Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed grade 1 or 2 follicular lymphoma (FL) or marginal zone
lymphoma (MZL)

- Stage III or IV disease

- Measurable or evaluable disease

- Previously untreated disease

PATIENT CHARACTERISTICS:

- ECOG performance status 1-3

- ANC > 1,000/mm³

- Platelet count > 100,000/mm³ (unless due to lymphoma)

- Bilirubin < 2.0 mg/dL

- Creatinine < 2 mg/dL (unless due to lymphoma)

- AST, ALT, and alkaline phosphatase < 3 times upper limit of normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No myocardial infarction within the past 6 months

- No NYHA class III-IV heart failure

- No uncontrolled angina

- No severe uncontrolled ventricular arrhythmias

- No ECG evidence of acute ischemia or active conductive system abnormalities

- No hypersensitivity to boron or mannitol

- No serious medical or psychiatric illness likely to interfere with participation in
this clinical study

- No history of HIV infection

- No concurrent or previous malignancy with poor prognosis (< 90% probability of
survival at 5 years) or actively treated for a second malignancy

- No peripheral neuropathy ≥ grade 2 within the past 14 days

PRIOR CONCURRENT THERAPY:

- No prior therapy for this disease including chemotherapy, single-agent rituximab, or
radiotherapy

- No other concurrent anticancer therapy including chemotherapy, radiation, hormonal
treatment, or immunotherapy

- At least 14 days since prior and no other concurrent investigational drugs

- No concurrent participation in another clinical study